

Ref: STEX/OUTCOME/2024-25

Date: 14.11.2024

<b>BSE Limited</b> <b>25th Floor</b> <b>Phiroze Jeejebhoy Towers Dalal Street,</b> <b>Mumbai 400 001</b>  <b>BSE Code-531146</b>	<b>National Stock Exchange of India Limited</b> <b>Exchange Plaza, C-1,</b> <b>Block - G Bandra Kurla</b> <b>Complex Bandra (East)</b> <b>Mumbai – 400 051</b>  <b>NSE Code: MEDICAMEQ</b>
---	--

**Sub. : Outcome of Board Meeting**

Dear Sir,

In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations'), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2024, were approved by the Board of Directors of the Company at its meeting held today at 2:00 P.M. and concluded at 04.15 P.M.

Pursuant to the applicable provisions of the Listing Regulations, we enclose the following:

- The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2024; as **(Annexure- A)**
- Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter as **(Annexure-B)**
- An Investor release on the financial results is enclose as **(Annexure-C)**

We request you to take the same on record.

The Un-audited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended on September 30, 2024, as approved by the Board, will also be available on the Company's website [www.medicamen.com](http://www.medicamen.com).

This is for your information and records.

Thanking You.

Yours faithfully,  
**For Medicamen Biotech Limited**

**Parul Choudhary**  
**Company Secretary**  
**ACS44157**



## MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

Unaudited Standalone and Consolidated Financial Results for the Quarter ended 30th Sept '2024

### PART I

Rupees in Lac (Except per Share Data)

Particulars	Standalone						Consolidated					
	Three Month period Ended			Half Year		Year Ended	Three Month period Ended			Half Year		Year Ended
	30.09.2024 Unaudited	30.06.2024 Unaudited	30.09.2023 Unaudited	30.09.2024 Unaudited	30.09.2023 Unaudited	31.03.2024 Audited	30.09.2024 Unaudited	30.06.2024 Unaudited	30.09.2023 Unaudited	30.09.2024 Unaudited	30.09.2023 Unaudited	31.03.2024 Audited
<b>1</b> Income from operations												
(a) Net Sales / Income from operations	4,284.39	4,148.17	4267.1	8,432.56	8,317.44	17,238.62	4,474.34	4,304.86	4,354.14	8,779.20	8,548.45	17,930.62
(b) Other Income	28.96	57.52	54.98	86.48	92.90	230.26	28.96	58.63	54.98	87.59	92.90	232.57
(c) Total Revenue	<b>4,313.35</b>	<b>4,205.69</b>	<b>4,322.08</b>	<b>8,519.04</b>	<b>8,410.34</b>	<b>17,468.88</b>	<b>4,503.30</b>	<b>4,363.49</b>	<b>4,409.12</b>	<b>8,866.79</b>	<b>8,641.35</b>	<b>18,163.19</b>
<b>2</b> Expenses												
a) Cost of Material Consumed	2,862.12	2,142.37	2750.96	5,004.49	5,332.80	10,469.80	2,894.44	2,166.57	2,766.87	5,061.01	5,377.72	10,469.80
b) Purchase of Goods Traded	-	-	0	-	-	-	-	-	-	-	-	-
c) Changes in inventory of Finished Goods and Work in Progress	(450.35)	237.71	-451.77	(212.64)	(975.83)	(1,331.70)	(450.34)	242.61	(451.69)	(207.73)	(975.83)	(1,210.03)
d) Employees Benefits Expenses	512.80	547.87	522.66	1,060.67	1,047.31	2,211.84	763.43	783.55	709.84	1,546.98	1,366.23	3,006.58
e) Finance Cost	101.17	67.85	90.72	169.02	186.37	437.71	104.10	70.57	90.72	174.67	186.37	439.72
f) Depreciation and Amortisation Expenses	257.22	174.21	179.62	431.43	347.59	700.84	260.73	177.03	182.31	437.76	351.39	709.32
g) Other expenses	704.96	734.17	829.85	1,439.13	1,556.73	3,291.60	735.30	767.53	864.62	1,502.83	1,620.69	3,440.24
Total Expenses	<b>3,987.93</b>	<b>3,904.18</b>	<b>3,922.04</b>	<b>7,892.10</b>	<b>7,494.97</b>	<b>15,780.09</b>	<b>4,307.66</b>	<b>4,207.86</b>	<b>4,162.67</b>	<b>8,515.52</b>	<b>7,926.57</b>	<b>16,855.63</b>
<b>3</b> Profit/(Loss) before Exceptional Items & Tax (1 - 2)	325.42	301.51	400.04	626.94	915.37	1,688.79	195.64	155.63	246.45	351.27	714.78	1,307.56
<b>4</b> Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-	-	-
<b>5</b> Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	325.42	301.51	400.04	626.94	915.37	1,688.79	195.64	155.63	246.45	351.27	714.78	1,307.56
<b>6</b> Tax Expenses												
Current Year	105.25	83.56	119.34	188.81	243.96	421.69	105.25	83.56	119.34	188.81	243.96	421.69
MAT Credit Entitlement	-	-	0	-	-	-	-	-	-	-	-	-
Deferred Tax Liability	(6.74)	(7.80)	-20.46	(14.54)	(71.45)	(62.70)	-	(7.80)	(20.56)	(14.54)	(71.55)	(63.53)
Total Tax Expense	98.52	75.76	98.88	174.27	172.51	358.99	105.25	75.76	98.78	174.27	172.41	358.16
<b>7</b> Net Profit /Loss for the period from Continuing operation (5- 6)	226.90	225.75	301.16	452.67	742.86	1,329.80	90.39	79.87	147.67	177.00	542.37	949.40


Particulars	Standalone						Consolidated					
	Three Month period Ended			Half Year		Year Ended	Three Month period Ended			Three Month period Ended		Year Ended
	30.09.2024 Unaudited	30.06.2024 Unaudited	30.09.2023 Unaudited	30.09.2024 Unaudited	30.09.2023 Audited	31.03.2024 Unaudited	30.09.2024 Unaudited	30.06.2024 Unaudited	30.09.2023 Unaudited	30.09.2024 Unaudited	30.09.2023 Audited	31.03.2024 Audited
8 Other Comprehensive Income Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	226.90	225.75	301.16	452.67	742.86	1,329.80	90.39	79.87	147.67	177.00	542.37	949.40
10 Net Profit /Loss attributable to												
a) Controlling Interest	-	-	-	-	-	-	145.64	135.12	151.34	232.25	569.09	1,093.10
b) Non-controlling Interest	-	-	-	-	-	-	(55.25)	(55.25)	173.25	(55.25)	(98.27)	(143.70)
10 Paid up equity share capital (Rs. 10/- per share)	1,271.46	1,271.46	1,265.11	1,271.46	1,265.11	1,271.46	1,271.46	1,271.46	1,265.11	1,271.46	1,265.11	1,271.46
11 Earning Per Share (Rs.)												
Basic	1.78	1.78	2.38	3.56	5.87	10.50	0.71	0.63	1.17	1.39	4.29	7.50
Diluted	1.78	1.78	2.38	3.56	5.87	10.50	0.71	0.63	1.17	1.39	4.29	7.50

**NOTES :**

- The Un-audited financial results for the quarter ended 30.09.2024 have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2024.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules,2015 (Ind AS) prescribed under Section 133 of the Companies Act,2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The other expenses includes salary & other marketing expenses for domestic market and marketing expense for setting up network of Oncology Market.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 -"Earning per Share".
- Limited Review has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*R. Bishnoi*  
(Rahul Bishnoi)  
Chairman

Place : New Delhi  
Dated : 14.11.2024



**MEDICAMEN BIOTECH LIMITED**

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, Website: www.medicamen.com

**STATEMENT OF ASSETS & LIABILITIES**

All Figures in Rs. Lacs

Particulars	Standalone		Consolidated	
	As at Sep 30,2024 Un-audited	As at Mar 31,2024 Audited	As at Sep 30,2024 Un-audited	As at Mar 31,2024 Audited
<b>A ASSETS</b>				
<b>1 Non-current assets</b>				
(a) Property, Plant and Equipment	8,696.10	9,020.61	8,779.55	9,095.18
(b) Intangible assets	92.34	89.83	92.34	89.83
(c) Capital work-in-progress	-	-	-	-
(d) Financial Assets : Investments	1,015.65	775.65	-	-
(e) Financial Assets : Loans and advances	120.19	120.19	120.19	121.91
(f) Deferred Tax liabilities (Net)	249.22	249.22	249.22	248.62
(g) Other Non- current assets	3,932.99	3,928.37	3,932.99	3,937.33
<b>Total Non-current Assets</b>	<b>14,106.49</b>	<b>14,183.87</b>	<b>13,174.29</b>	<b>13,492.87</b>
<b>2 Current assets</b>				
(a) Inventories	5,996.97	5,932.62	5,996.97	5,937.52
(b) Financial Assets				
(i) Current investments	-	-	-	-
(ii) Trade receivables	4,836.37	4,828.58	5,664.44	5,525.93
(iii) Cash and Bank Balances	625.27	1,462.03	641.50	1,478.56
(iv) Loans and advances	391.26	447.80	424.33	449.34
(c) Other current assets	2,940.00	2,566.29	2,949.61	2,568.02
<b>Total current Assets</b>	<b>14,789.87</b>	<b>15,237.32</b>	<b>15,676.85</b>	<b>15,959.37</b>
<b>Total Assets</b>	<b>28,896.36</b>	<b>29,421.19</b>	<b>28,851.14</b>	<b>29,452.24</b>
<b>B EQUITY AND LIABILITIES</b>				
<b>1 Equity</b>				
(a) Equity share capital	1,271.46	1,271.46	1,271.46	1,271.46
(b) Other Equity	20,776.01	19,649.10	20,320.02	18,777.11
<b>Total Equity</b>	<b>22,047.47</b>	<b>20,920.56</b>	<b>21,591.48</b>	<b>20,048.57</b>
<b>LIBILITIES</b>				
<b>2 Non-current Liabilities</b>				
(a) Financial Liabilities : Borrowings	105.73	95.07	139.98	125.55
(b) Provisions	239.40	175.58	239.40	175.58
(c) Deferred Tax liabilities (Net)	-	-	0.60	-
<b>Total Non-current Liabilities</b>	<b>345.13</b>	<b>270.64</b>	<b>379.98</b>	<b>301.13</b>
<b>3 Current Liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	1,785.71	2,863.57	1,876.85	2,956.17
(ii) Trade payables	4,238.96	3,797.43	4,489.60	4,541.88
(b) Other current liabilities	59.92	1,070.44	67.09	1,105.93
(c) Provisions	12.88	92.28	39.87	92.28
(c) Current Tax Liabilities (Net)	406.29	406.28	406.29	406.28
<b>Total Current Liabilities</b>	<b>6,503.76</b>	<b>8,230.00</b>	<b>6,879.69</b>	<b>9,102.54</b>
<b>Total Equity and Liabilities</b>	<b>28,896.36</b>	<b>29,421.19</b>	<b>28,851.14</b>	<b>29,452.24</b>
	-	-	0.00	-

For & on behalf of Board of Directors

Medicamen Biotech Limited



*R. Bishnoi*  
(Rahul Bishnoi)  
Chairman

Place : New Delhi

Dated : 14.11.2024

**MEDICAMEN BIOTECH LIMITED**

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

**STANDALONE CASH FLOW STATEMENT FOR THE PERIOD 01.04.2024 TO 30.09.2024**

Particulars	Standalone		Consolidated	
	For the Half year ended 30th Sept, 2024	For the year ended 31st March, 2024	For the Half year ended 30th Sept, 2024	For the year ended 31st March, 2024
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>				
Net Profit/(Loss) after tax from continuing operations	452.67	1,329.80	177.00	949.40
Non-cash adjustment to reconcile profit before tax to net cash flows				
Provision for Taxation	188.81	421.69	188.81	421.69
Adjustment for Deferred Tax	-14.54	-62.70	-14.54	-63.53
Financial Charges	169.02	437.71	174.67	439.72
Loss/(profit) on sale of fixed assets	-	-0.03	-	0.03
Depreciation/amortization on continuing operation	431.43	700.84	437.76	709.32
Interest income	-86.48	-71.42	-9.94	-72.43
<b>Operating profit before working capital changes</b>	<b>1,140.91</b>	<b>2,755.90</b>	<b>953.76</b>	<b>2,384.21</b>
Movement of working capital				
Increase/(decrease) in trade payables	441.53	-753.31	-52.28	-216.70
Increase / (decrease) in long-term provisions	63.82	9.57	63.82	0.34
Increase / (decrease) in short-term provisions	-268.20	-365.92	-241.21	-362.12
Increase/(decrease) in other current liabilities	-1,010.52	349.61	-1,038.84	377.47
Decrease/(increase) in trade receivables	-7.79	1,193.96	-138.51	999.88
Decrease/(increase) in inventories	-64.35	-1,426.89	-59.45	-1,431.79
Decrease / (increase) in long-term loans and advances	-	-11.25	1.72	-11.25
Decrease / (increase) in short-term loans and advances	56.54	242.55	175.01	243.25
Decrease/(increase) in other current assets	-373.71	274.21	-367.65	272.74
Decrease/(increase) in other Non-current assets	-4.62	-1,986.52	4.34	-1,986.11
Direct taxes paid	-	-306.50	-150.00	-306.50
<b>Net cash flow from/ (used in) operating activities (A)</b>	<b>-26.39</b>	<b>-24.60</b>	<b>-849.30</b>	<b>-36.58</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>				
Purchase of fixed assets including intangible & CWIP	-109.43	-574.91	-124.64	-628.68
Purchase of non-current investments	-240.00	-368.00	-	-
Interest received	86.48	71.42	9.94	72.43
<b>Net cash flow from/(used in) investing activities (B)</b>	<b>-262.95</b>	<b>-871.49</b>	<b>-114.70</b>	<b>-556.25</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES :</b>				
Proceeds from issuance of share capital	-	6.35	-	6.35
Proceeds from Securities Premium	-	331.33	-	183.32
Capital Reserve	-	-	106.14	-
Shares Warrants	-	-	-	-293.37
Long-term borrowings net of repayment / Repayment	10.66	8.11	14.44	38.59
Proceeds from short-term borrowings	-389.06	532.26	181.03	624.86
Interest paid	-169.02	-437.71	-174.67	-439.72
Dividends paid on equity shares	-	-126.51	-	-126.51
Income Tax Provision reverse for earlier year	-	-	-	-
Preferential issue Expenditure	-	-	-	-
<b>Net cash flow from/(used in) in financing activities (C)</b>	<b>-547.42</b>	<b>313.83</b>	<b>126.94</b>	<b>-6.48</b>
Net increase/(decrease) in cash and cash equivalents (A + B + C)	-836.76	-582.26	-837.06	-599.32
Cash and cash equivalents at the beginning of the year	1,462.03	2,044.29	1,478.56	2,077.88
<b>Cash and cash equivalents at the end of the year</b>	<b>625.27</b>	<b>1,462.03</b>	<b>641.50</b>	<b>1,478.56</b>

For & on behalf of Board of Directors  
Medicamen Biotech Limited



*(Rahul Bishnoi)*  
Chairman

Place : New Delhi

Dated : 14.11.2024



# RAI QIMAT & ASSOCIATES

## CHARTERED ACCOUNTANTS



### LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY STANDALONE FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To

**The Board of Directors,  
Medicamen Biotech Ltd.**  
1506, Chiranjiv Tower, 43  
Nehru Place, New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of M/s Medicamen Biotech Limited having its registered office situated at 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019 for the quarter and half year ended on September 30, 2024 ("the statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS - 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), and other accounting principles generally accepted in India and in compliance with Regulation 33 and Regulation 52 read with Regulation 63(2) of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rai Qimat & Associates  
Chartered Accountants**



**(Membership Number: 013152C)  
UDIN:24080857BKFGGY7954**

**Place: Gurugram  
Date: 14.11.2024**



**LIMITED REVIEW REPORT ON UNAUDITED QUARTERLY CONSOLIDATED FINANCIAL RESULTS OF MEDICAMEN BIOTECH LIMITED UNDER REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To

**The Board of Directors,  
Medicamen Biotech Ltd.**  
1506, Chiranjiv Tower, 43  
Nehru Place, New Delhi-110019

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MEDICAMEN BIOTECH LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associate for the quarter and half year ended on September 30, 2024 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

5. The Statement includes the results of the Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited ( the "Subsidiary" Company)
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 and 7(ii) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and

other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. The Statements includes the Group's share of net profit/(loss) after tax of Rs. (2.76) Crores for the quarter and half year ended on September 30, 2024, as considered in the consolidated unaudited financial results, in respect of its subsidiaries, based on their interim financial information which has not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial informations are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

Our conclusion on the Statement is not modified in respect of the above matter.

**For Rai Qimat & Associates  
Chartered Accountants**



**Qimat Rai Garg  
Partner  
(Membership Number: 013152C)  
UDIN:24080857BKFGGZ3870**

**Place: Gurugram  
Date: 14.11.2024**





# Medicamen Biotech Limited

Q2, 2024

# Our Journey till date - Medicamen

## 2017-2019

- ▶ Initiate modernisation of Bhiwadi plant (India) compatible to EU standards
- ▶ Appointed new managerial team at corporate office, manufacturing plant, and R&D center.

## 2020 - 2022

- ▶ Opened dedicated Oncology Formulation Plant at Haridwar (India)
- ▶ Completed capacity expansion at Bhiwadi plant
- ▶ Formed new distribution subsidiary for India, Medicamen Lifesciences, with team of 110 team, for

## 2023 – till date

- ▶ Granted US-FDA approval for Oncology formulation plant at Haridwar
- ▶ Granted EU GMP (from Greece) approval for Bhiwadi plant
- ▶ Applied for desktop approval in Australia
- ▶ Filed first ANDA with US-FDA for Bortezomib injection 3.5mg



# Growth Drivers Unlocking Future Value

## Oncology Segment

- ▶ Introduced a specialized oncology brand for Indian market - Vivo Oncology
- ▶ Launched 12 products and successfully penetrated 16 cities across Northern and Western India
- ▶ Supplying to top institutions like Tata Memorial (Mumbai), Rajiv Gandhi Cancer Institute (Delhi), AIIMS, Max, Fortis.

## Global Expansion

- ▶ Implementing a dual-distribution strategy leveraging internal sales with strategic partnerships
- ▶ To launch 10 non-oncology formulations for European Union market
- ▶ Filed first ANDA with US-FDA for Bortezomib injection

## Domestic Market

- ▶ Launched Medicamen Lifesciences, a subsidiary focused on marketing Cardio-Vascular and diabetic (CVD) and pain management products in Indian market
- ▶ Strong presence across Indian cities with growing distribution network nationwide

**30**

Senior personnel

**53**

SKUs

**160**

Products registered

**280**

Products under registration and filing

**100**

Employee team

**74**

SKUs

# Global Footprint

100+ products are currently available in over **25** countries...

... approval of ongoing registrations and filings will unlock newer markets and expand product offerings

## Latin America

- ▶ Brazil
- ▶ Cuba
- ▶ Dominic Republic
- ▶ Curacao
- ▶ Jamaica
- ▶ Haiti

## Asia Pacific\*

- ▶ Afghanistan
- ▶ Bhutan
- ▶ Cambodia
- ▶ Philippines
- ▶ Myanmar
- ▶ Nepal
- ▶ Sri Lanka
- ▶ Australia
- ▶ Kyrgyzstan
- ▶ Tajikistan

## Africa

- ▶ Cameroon
- ▶ Congo
- ▶ Ethiopia
- ▶ Ghana
- ▶ Ivory cost
- ▶ Kenya
- ▶ Malawi
- ▶ Namibia
- ▶ Nigeria
- ▶ South Sudan
- ▶ Uganda
- ▶ Zambia
- ▶ Zimbabwe



Filed first ANDA with US-FDA for Bortezomib injection 3.5mg



7 products developed and filed  
4 products under registration and filing  
4 products under development in R&D



Products registration received  
7 in Mali  
5 in Zimbabwe

Products filed  
40 in Ethiopia  
20 in Mozambique  
50 in Ghana  
8 in Namibia  
40 Cameroon



Prepared to file 5 dossiers in Australia pending desktop approval confirmation




# Manufacturing facilities: Three cutting-edge plants developing finished dosage forms

## Bhiwadi, Rajasthan

- ▶ A six-block contemporary facility for general formulations
- ▶ Dedicated research and development block for formulation development
- ▶ Distinct block to store finished goods
- ▶ 210,000 sq. feet area

EU GMP (Greece) approved facility  
WHO GMP certified  
ISO certified



## Haridwar Unit I, Uttarakhand (General)

- ▶ Focused on general formulations - diverse finished dose forms
- ▶ Houses a well-developed quality control (QC) lab
- ▶ 32,000 sq. feet area

WHO GMP certified

## Haridwar Unit II, Uttarakhand (Oncology)

- ▶ State-of-the-art facility dedicated to Oncology formulations – lyophilized and ready to use formulations
- ▶ 35,000 sq. feet area

US-FDA approved facility  
WHO GMP certified



Bhiwadi



Haridwar I



Haridwar II



## Targeted marketing investments

We are strategically reinvesting our cash flow to drive long-term growth by expanding our marketing efforts.

This includes launching a domestic distribution subsidiary with a team of over 100 employees and building a dedicated oncology brand with more than 30 experts, all designed to position us for sustained success and leadership in the market.

## Product/ Dossier Registration Investments

Our expanding product registrations and dossier submissions, while capital intensive, will unlock new opportunities in more regulated markets.

While African clients currently account for 70% of our sales, we are expanding into European, U.S. and Middle East markets in the medium term, which will significantly drive the growth.





## Medicamen Biotech Limited

### Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500 (30 Lines)

Fax: 011-26213081

E-mail: [vk@medicamen.com](mailto:vk@medicamen.com)

Website: [www.medicamen.com](http://www.medicamen.com)

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Medicamen Biotech Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.